Reassessment by IQWiG finds Xalkori (Pfizer) may offer considerable benefit for ALK+ NSCLC
The Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed additional information on Xalkori (crizotinib), from Pfizer, for treatment of Non Small Cell Lung Cancer (NSCLC) and the result of the benefit assessment has changed. In contrast to the first dossier assessment, the IQWiG now considers there to be a hint of a considerable added benefit in symptoms and in quality of life of crizotinib in comparison with chemotherapy.
In February 2013 a preliminary benefit assessment by the IQWiG found that Xalkori provides "no additional benefit" over docetaxel or pemetrexed-containing chemotherapy in patients with previously treated, advanced NSCLCancer whose tumors are anaplastic lymphoma kinase (ALK)-positive, which is Xalkori's approved indication.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.